$46 Million

Marinus Pharmaceuticals

Follow-on Offering

Lead Left Bookrunner, May 2020

Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on developing and commercializing innovative therapeutics to treat patients suffering from rare seizure disorders. The Company’s clinical stage product candidate, ganaxolone, is a positive allosteric modulator of GABAA that is being developed in formulations for two different routes of administration: intravenous (IV) and oral. The Company is exploring the use of ganaxolone in two classes of disorders: seizure disorders and depressive disorders. Additionally, the Company is exploring the use of oral ganaxolone for the treatment of CDKL5 deficiency disorder (CDD), a serious and rare genetic disorder that is caused by a mutation of the cyclin dependent kinase like 5 (CDKL5) gene, located on the X chromosome.